Form 4: Vertex Pharmaceuticals SVP Kristen Ambrose Reports Stock Transactions
SEC Form 4 Filing
Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of shares to cover tax obligations and a sale under a pre-arranged trading plan.
Summary
- Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 14, 2025, 564 shares of common stock were disposed of to cover tax obligations at a price of $463.46 per share.
- On February 18, 2025, 671 shares of common stock were sold at a price of $455.06 per share.
- Following these transactions, Ms. Ambrose beneficially owns 10,798 shares of Vertex Pharmaceuticals common stock.
- The sale on February 18, 2025, was executed under a pre-arranged trading plan (Rule 10b5-1) established on August 8, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reflects routine transactions under a pre-arranged trading plan and tax obligations.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 trading plan suggests a pre-planned and compliant approach to stock sales.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date of entry into Rule 10b5-1 trading plan |
| 02/14/2025 | Disposition of 564 shares for tax obligations |
| 02/18/2025 | Sale of 671 shares under Rule 10b5-1 trading plan |
| 02/19/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.